This content is protected against AI scraping.
The DEA’s cannabis rescheduling hearing is officially in the books—and now 2,500+ pages of testimony are public. The 11-day hearing centered on one major question: should cannabis remain a Schedule I drug, where it has been classified alongside drugs like heroin, or move to Schedule III, a less restrictive category that recognizes accepted medical use? The hearing included doctors, researchers, law enforcement officials and other experts, with seven designated groups arguing against rescheduling.
What makes this especially interesting is how much the DEA’s position has changed. The agency spent years resisting the move to Schedule III, but in this 2026 proceeding, the DEA itself is now defending the proposal. The agency presented witnesses and evidence in support of moving cannabis to Schedule III, while only opponents were allowed to participate as designated parties in the hearing.
Now the hearing is over, and the next step is a big one. Administrative Law Judge Derek C. Julius will review the evidence and issue a nonbinding recommendation on whether cannabis should remain Schedule I or move to Schedule II or III. The parties involved can challenge his findings before the recommendation goes to DEA Administrator Terry Cole for a final decision. For now, nothing has changed for consumers or businesses. Cannabis remains federally illegal, and rescheduling—even if it happens—would not make it legal. It would simply move cannabis into a different category under federal law.
This is a summary.
Please read the original article: DEA Judge Releases Transcripts for Cannabis Rescheduling Hearing
Original article written by Tony Lange. Published on August 25, 2026 by Cannabis Business Times.







